Chronic Myeloid Leukemia Monitoring after Imatinib Failure: Still More Questions than Answers

Publisher： Karger

E-ISSN： 1421-9662|134|4|246-247

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.4, 2015-0, pp. : 246-247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-09 ,pp. : 18-19

Karger

Access to resources Recommend Favorite

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

By Saleh Mansoor N.   Haislip Sally   Sharpe Joyce   Hess Tamara   Gilmore James   Jackson James   Sail Kavita R.   Ericson Solveig G.   Chen Lei  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 529-536

Informa Healthcare

Access to resources Recommend Favorite

More Questions than Answers: The Commodification of Health Care

By Wildes   S.J. Kevin Wm  

The Journal of Medicine and Philosophy, Vol. 24, Iss. 3, 1999-06 ,pp. : 307-311

Oxford University Press

Access to resources Recommend Favorite

Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 354-364

Karger

Access to resources Recommend Favorite

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite